Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJACXN)

• Drug Name: HRC-102 Drug Info
• Synonyms: Hemolox T; HML-110

Indication

Disease Entry	ICD 11	Status	REF
Reperfusion injury	ND56.Z	Terminated	[1]

• Cross-matching ID: TTD Drug ID: DMJACXN

Molecule-Related Drug Atlas

Drug(s) Targeting Hemoglobin (HB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Voxelotor	DMCS6M5	Sickle-cell disorder	3A51	Approved	[3]
Iron	DMAP8MV	Anemia of prematurity		Approved	[4]
Iron Dextran	DM5OY70	Iron-deficiency anemia	3A00	Approved	[4]
PolyHeme	DMV8EXG	Blood forming organ disorder	JB64.1	Phase 3	[5]
Efaproxyn	DMX7BM4	Lung cancer	2C25.0	Phase 3	[6]
Hemoglobin raffimer	DMMTL7V	Anemia	3A00-3A9Z	Phase 2/3	[7]
GBT021601	DMD3C21	Sickle-cell disorder	3A51	Phase 2/3	[8]
FBS-0701	DMR3952	Iron overload disease	5C64.10	Phase 2	[9]
HQK-1001	DM7QUN0	Beta thalassemia	3A50.2	Phase 2	[10]
5-hydroxymethyl-2-furfural	DMPFVJB	Anemia	3A00-3A9Z	Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hemoglobin (HB)	TTQO71U	HBA_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016740)
• [2] WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [4] Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7.
• [5] Blood substitutes- the polyheme trials. Mcgill J Med. 2008 January; 11(1): 59-65.
• [6] Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9.
• [7] Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah's Witness. Can J Anaesth. 2005 Apr;52(4):369-73.
• [8] GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. Br J Haematol. 2023 Jul;202(1):173-183.
• [9] A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 1;15(23):7144-52.
• [10] A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in beta-thalassaemia intermedia. Br J Haematol. 2014 Feb;164(3):456-8.
• [11] 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 2005 Feb;128(4):552-61.